# Shanghai Bioprofile

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-bioprofile

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Series A (Aug 25, 2023)
- Investors on record: 2

## About

Established in 2017 and based in Shanghai, China, Shanghai Bioprofile is a provider of precision medicine services that provides proteomics, metabolomics, genomics and transcriptome technical services. The company has been recognized as a National High-tech Enterprise, and has obtained ISO9001 quality system certification, 11 patents and 10 registered trademarks. It has strategic cooperation with Wuhan University, Peking University, Fudan University, Ruijin Hospital, Wuhan Institute of Virology, and other universities, hospitals and institutes. In August 2023, Shanghai Bioprofile raised a series A funding led by new investor Zhonghuijin Group, with participation from returning investor Step Venture Capital.

The company's technology platforms include Triple-TOF 5600, QE-HF X, GC-MS, Orbitrap_Velos, Orbitrap Fusion Lumos, timsTOF Pro, and Q-Extacive HF. The platforms are capable of providing scientific research services and medical testing services in proteomics, metabolomics, genomics and transcriptomics, involving multiple applications such as precision diagnostics, precision medication, and precision screening of drug targets.

Shanghai Bioprofile will focus on the R&D and production of Class II and Class III reagent kits, and will set up a 3,000 square meters clinical mass spectrometry-related GMP workshop and medical laboratory, as well as IVD-specific R&D laboratories and research service laboratories.

## Funding rounds

- Series A, Aug 25, 2023 — Step Venture Capital, Zhonghuijin Group

## Investors

- Step Venture Capital (https://capitalatlas.ai/funds/step-venture-capital) — Series A
- Zhonghuijin Group — Series A